Approval for Parecoxib Sodium API and Parecoxib Sodium for Injection of China Meheco Sanyang Pharma Co., Ltd.

China Meheco Sanyang Pharma Co., Ltd., a subsidiary of China Meheco Group Co., Ltd., has received the Drug Registration Certificate for Parecoxib Sodium for Injection (40 mg) (Certificate No. 2021S00824) issued by the National Medical Products Administration (NMPA), which is regarded as qualified for the consistency evaluation. Meanwhile, Parecoxib Sodium API has also been approved for drug filing, with a review and approval result of A.

As a Non-Steroidal Anti-Inflammatory Drug (NSAID), Parecoxib Sodium is primarily indicated for the short-term treatment of postoperative pain. With the acquisition of the Drug Registration Certificate for Parecoxib Sodium for Injection in accordance with the New Chemical Drug Registration Classification, it is not only helpful to enhance the Company's market competitiveness in this pharmaceutical field, but also has accumulated valuable experience for the Company's subsequent generic drug development.